Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | TLR3 | O15455 | 1/20 | 0.43 |
| ▸ | TLR5 | O60602 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8902614 | 0.82 | MYC (0.40) | BRD4IDO1SGMS2MAPTMAPK1 | |
| SCHEMBL2123412 | 0.81 | TTR (0.46) | PDE5AMAPT | |
| SCHEMBL26013299 | 0.77 | MAPT (0.63) | BRD4IDO1SGMS2MAPTMAPK1 | |
| SCHEMBL28284772 | 0.76 | ADRA1D (0.58) | BRD4CNR1CNR2IDO1SGMS2 | |
| SCHEMBL5947678 | 0.76 | NCOA1 (0.41) | BRD4MAPTMAPK1LTA4H | |
| SCHEMBL5651360 | 0.75 | BRD4 (0.52) | BRD4CNR1CNR2IDO1SGMS2 | |
| SCHEMBL29840676 | 0.75 | METAP2 (0.49) | CNR2MAPTL3MBTL1 | |
| SCHEMBL2124969 | 0.75 | METAP2 (0.49) | CNR2MAPTL3MBTL1 | |
| SCHEMBL14527078 | 0.75 | ALDH1A1 (0.53) | BRD4IDO1PDE5APDE4APDE4B | |
| SCHEMBL10969614 | 0.75 | ALDH1A1 (0.53) | BRD4IDO1PDE5APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| EP-3045912-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| US-10006904-B2 | Rapid quantitative assay to measure CFTR function in a primary intestinal culture model | UMC UTRECHT HOLDING B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| EP-3045912-A1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC Utrecht Holding B.V. (NL) | 2016-07-20 | — | — | EP | disclosed |
| EP-2795322-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2015-12-09 | — | — | EP | disclosed |
| US-20150276719-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-10-01 | — | — | US | disclosed |
| US-20150011420-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2015-01-08 | — | — | US | disclosed |
| EP-2795322-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC Utrecht Holding B.V. (NL) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093812-A2 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING B.V. (NL) | 2013-06-27 | — | — | WO | disclosed |
| EP-1594870-A1 | SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS | Tibotec Pharmaceuticals Ltd. (IE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005086954-A2 | CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED METHODS FOR TREATING DISEASE | YALE UNIVERSITY (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040266883-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2004-12-30 | — | — | US | disclosed |
| WO-2004046143-A1 | SUBSTITUTED INDOLEPYRIDINIUM AS ANTI-INFECTIVE COMPOUNDS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266883-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | HSPA5, ERP44, ATP2A2 | BRD4 2590/4885CNR1 2629/4885CNR2 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.